DK1341524T3 - Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel - Google Patents

Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel

Info

Publication number
DK1341524T3
DK1341524T3 DK01991781.4T DK01991781T DK1341524T3 DK 1341524 T3 DK1341524 T3 DK 1341524T3 DK 01991781 T DK01991781 T DK 01991781T DK 1341524 T3 DK1341524 T3 DK 1341524T3
Authority
DK
Denmark
Prior art keywords
paste
acid
active ingredient
labile active
pharmaceutical composition
Prior art date
Application number
DK01991781.4T
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK1341524T3 publication Critical patent/DK1341524T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
DK01991781.4T 2000-12-07 2001-12-05 Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel DK1341524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126828 2000-12-07
PCT/EP2001/014253 WO2002045686A2 (en) 2000-12-07 2001-12-05 Pharmaceutical paste comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
DK1341524T3 true DK1341524T3 (da) 2012-01-16

Family

ID=8170595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01991781.4T DK1341524T3 (da) 2000-12-07 2001-12-05 Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel

Country Status (15)

Country Link
US (1) US7988999B2 (da)
EP (1) EP1341524B1 (da)
JP (1) JP4241041B2 (da)
KR (1) KR20030059314A (da)
CN (1) CN100536844C (da)
AT (1) ATE529097T1 (da)
AU (1) AU2002231654A1 (da)
BR (1) BR0115985A (da)
CA (1) CA2430816C (da)
CY (1) CY1112510T1 (da)
DK (1) DK1341524T3 (da)
ES (1) ES2375269T3 (da)
PT (1) PT1341524E (da)
SI (1) SI1341524T1 (da)
WO (1) WO2002045686A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
RS52908B (en) 2003-03-10 2014-02-28 Takeda Gmbh NEW PROCEDURE FOR OBTAINING ROFLUMILAST
WO2004096282A1 (ja) * 2003-05-02 2004-11-11 Junya Fujimori 親水性ブレンドゲル
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN101052360B (zh) * 2003-09-23 2012-05-16 奥索康公司 可吸收的植入体和它们用于止血和治疗骨缺损的方法
CA2554260A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
WO2006097456A1 (en) * 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008045920A2 (en) 2006-10-10 2008-04-17 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
CN105944095B (zh) * 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
WO2010118142A1 (en) * 2009-04-08 2010-10-14 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
EP2526931B1 (en) * 2011-05-23 2014-12-17 Deva Holding Anonim Sirketi Wet granulation methods of cetyl myristate and/or cetyl palmitate
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
US20220257772A1 (en) * 2019-07-19 2022-08-18 Spi Pharma, Inc. Preparation of lipophilic active ingredients

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
DE69229710T2 (de) * 1991-11-15 2000-03-02 Kanegafuchi Chemical Ind Esterbindung enthaltende Polymere für pharmazeutische Zubereitungen
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US20010051131A1 (en) * 1996-06-19 2001-12-13 Evan C. Unger Methods for delivering bioactive agents
JP2001511774A (ja) * 1997-01-29 2001-08-14 ジョンズ・ホプキンス・ユニバーシティー 診断学的及び治療学的適用のためのウレアーゼ反応性輸送系
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
PT1156806E (pt) 1999-02-23 2004-07-30 Merck & Co Inc Composicao farmaceutica contendo inibidores da bomba de protoes
TR200103527T2 (tr) 1999-06-07 2002-04-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Bir asit-labil aktif bileşik içeren yeni hazırlama ve uygulama şekli
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
KR20030032922A (ko) * 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6606234B1 (en) * 2000-09-05 2003-08-12 Saint-Gobain Ceramics & Plastics, Inc. Electrostatic chuck and method for forming an electrostatic chuck having porous regions for fluid flow
BR0115986A (pt) * 2000-12-07 2003-12-23 Altana Pharma Ag Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
ES2292634T3 (es) * 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Procedimiento de transicion de fase inducida para la produccion de microparticulas que contienen agentes hidrofilos activos.
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof

Also Published As

Publication number Publication date
CA2430816A1 (en) 2002-06-13
CY1112510T1 (el) 2015-12-09
CA2430816C (en) 2012-05-15
ATE529097T1 (de) 2011-11-15
CN1479611A (zh) 2004-03-03
US7988999B2 (en) 2011-08-02
CN100536844C (zh) 2009-09-09
JP4241041B2 (ja) 2009-03-18
BR0115985A (pt) 2003-12-23
ES2375269T3 (es) 2012-02-28
PT1341524E (pt) 2011-12-30
US20040101558A1 (en) 2004-05-27
WO2002045686A3 (en) 2002-12-12
EP1341524B1 (en) 2011-10-19
JP2004514733A (ja) 2004-05-20
WO2002045686A2 (en) 2002-06-13
EP1341524A2 (en) 2003-09-10
KR20030059314A (ko) 2003-07-07
SI1341524T1 (sl) 2012-02-29
AU2002231654A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
DK1341524T3 (da) Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
HUP0000976A2 (hu) Protonpumpa inhibitort tartalmazó, több egységből pezsgőtablettává préselt gyógyszeradagolási formák
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
EE05256B1 (et) Ravimpreparaat, milles aktiivne ingredient on ühtlaselt dispergeeritud abiainete alussegus, ning seda sisaldav doseerimisvorm
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ATE292453T1 (de) Antivirale arznei
HUP0400553A2 (hu) Gyógyászati készítmények
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
WO2005065639A3 (en) Novel pharmaceutical compositions
PT1414467E (pt) Tratamento topico da mastalgia
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
CA2429793A1 (en) Interferon therapeutic effect enhancer
ATE242626T1 (de) Wasserlösliche pharmazeutische darreichungsform, ausgenommen brause-formen, welche nicht- steroidale antientzündliche wirkstoffe enthält
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2003013441A3 (en) Levothyroxine compositions and methods
WO2004014318A3 (en) Levothyroxine compositions and methods
DE50005076D1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
BR0207299A (pt) Composição farmacêutica, solução aquosa e métodos para fabricar e para preparar uma composição, para instruir um humano a ingerir uma composição farmacêutica de liberação imediata e para tratar um humano